Choledocholithiasis is one of the most common indications for endoscopic retrograde cholangiopancreatography (ERCP) in daily practice. Although the majority of stones are small and can be easily removed in a single endoscopy session, approximately 10–15% of patients have complex biliary stones, requiring additional procedures for an optimum clinical outcome. A plethora of endoscopic methods is available for the removal of difficult biliary stones, including papillary large balloon dilation, mechanical lithotripsy, and electrohydraulic and laser lithotripsy. In-depth knowledge of these techniques and the emerging literature on them is required to yield the most optimal therapeutic effects. This narrative review aims to describe the definition of difficult bile duct stones based on certain characteristics and streamline their endoscopic retrieval using various modalities to achieve higher clearance rates.

The role of the gut microbiome (GM) and oral microbiome (OM) in cardiovascular disease (CVD) has been increasingly being understood in recent years. It is well known that GM is a risk factor for various CVD phenotypes, including hypertension, dyslipidemia, heart failure and atrial fibrillation. However, its role in valvular heart disease (VHD) is less well understood. Research shows that, direct, microbe-mediated and indirect, metabolite-mediated damage as a result of gut dysbiosis and environmental factors results in a subclinical, chronic, systemic inflammatory state, which promotes inflammatory cell infiltration in heart valves and subsequently, via pro-inflammatory molecules, initiates a cascade of reaction, resulting in valve calcification, fibrosis and dysfunction. This relationship between GM and VHD adds a pathophysiological link to the pathogenesis of VHD, which can be aimed therapeutically, in order to prevent or regress any risk for valvular pathologies. Therapeutic interventions include dietary modifications and lifestyle interventions, in order to influence environmental factors that can promote gut dysbiosis. Furthermore, the combination of probiotics and prebiotics, as well as fecal m transplantation and targeted treatment with inducers or inhibitors of microbial enzymes have showed promising results in animal and/or clinical studies, with the potential to reduce the inflammatory state and restore the normal gut flora in patients. This review, thus, is going to discuss the pathophysiological links behind the relationship of GM, CVD and VHD, as well as explore the recent data regarding the effect of GM-altering treatment in CVD, cardiac function and systemic inflammation.

Endoscopic full-thickness resection (EFTR) has emerged as a transformative technique for managing gastrointestinal (GI) lesions, previously deemed unsuitable for endoscopic removal. Unlike conventional endoscopic resection methods, such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), EFTR enables en bloc excision of both intraluminal and subepithelial lesions by resecting all layers of the GI wall, followed by defect closure to prevent complications. The introduction of the full-thickness resection device (FTRD^®) has significantly enhanced the feasibility and safety of EFTR, particularly in the colon and upper GI tract, with increasing adoption worldwide. This review provides a comprehensive analysis of FTRD^®, focusing on its clinical applications, procedural methodology, and comparative efficacy against other endoscopic resection techniques. The indications and contraindications for EFTR are explored, highlighting its utility in treating non-lifting adenomas, subepithelial tumours, and T1 carcinomas without lymph node involvement. This review synthesizes current clinical data and FTRD^® advantages. Despite its strengths, EFTR via FTRD^® incorporates challenges such as limitations in lesion size, procedural complexity, and potential adverse events. Strategies for overcoming these challenges, including hybrid techniques and modifications in procedural approach, are examined. The review also emphasizes the need for further research to optimize surveillance strategies and determine the long-term clinical impact of EFTR in GI lesion management. By integrating recent evidence, this paper provides valuable insights into the evolving role of EFTR in therapeutic endoscopy.

Background and Objectives: Early gastric cancer (EGC) has an excellent prognosis when detected, yet miss rates during endoscopy remain high. Narrow-band imaging (NBI) enhances mucosal and vascular visualization and is increasingly used, but its benefit over white-light imaging (WLI) in high-risk patients is uncertain. This study aimed to compare NBI with WLI for the detection of gastric neoplasia in patients undergoing gastroscopy. Materials and Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs), registered in PROSPERO (CRD42025649908) and reported according to PRISMA 2020 guidelines. PubMed, Scopus, and CENTRAL were searched up to October 2024. Eligible RCTs randomized adults undergoing gastroscopy for cancer surveillance or red-flag symptoms to NBI or WLI. Data extraction and risk of bias assessment were performed independently by two reviewers. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model, and certainty of evidence was graded with GRADE. Results: From 21 records, 3 RCTs comprising 6003 patients were included. NBI did not significantly increase gastric neoplasm detection compared with WLI (2.79% vs. 2.74%; RR = 0.98; 95% CI: 0.66–1.45; I² = 22%). Focal gastric lesion detection rates (14.73% vs. 15.50%; RR = 1.05; 95% CI: 0.72–1.52; I² = 87%) and positive predictive value (29.56% vs. 20.56%; RR = 1.29; 95% CI: 0.84–1.99; I² = 61%) also showed no significant differences. Risk of bias was high for blinding, and overall evidence certainty was low. In practical terms, both NBI and WLI detected gastric cancers at similar rates, indicating that while NBI enhances visualization, it does not increase the likelihood of finding additional cancers in high-risk patients. Conclusions: NBI did not significantly improve gastric neoplasm detection compared with WLI in high-risk patients, though it remains valuable for mucosal and vascular assessment. Larger, multicenter RCTs across diverse populations are required to establish its role in surveillance strategies.

Video Capsule Endoscopycapsule endoscopy (VCE) has emerged as a minimally invasive diagnostic tool for detecting and monitoring small bowel involvement in polyposis syndromes. VCE is included in the surveillance guidelines of Peutz-Jeghers syndrome. In the remaining familial polyposis syndromes, VCE may facilitate the early detection of polyps, when indicated, particularly in areas beyond the reach of conventional endoscopy, thereby aiding timely detection. Colon capsule endoscopy has been studied in symptomatic, screening and polyp surveillance populations and the second-generation colon capsule has demonstrated excellent detection rates for advanced neoplasia, however its role in colonic polyposis requires further research. The role of the panenteric capsule has not been explored in polyposis syndromes as a panintestinal examination. Despite its advantages, VCE has notable limitations; it may miss small, flat, or hidden lesions and lacks the capability for tissue sampling or therapeutic intervention. In the future, advances in imaging technology, extended battery life, and the integration of artificial intelligence (AI) are expected to further enhance the utility of VCE. Our review aims to focus on the applications of VCE in polyposis syndromes and future perspectives.

Varioliform gastritis (VG) is a rare chronic gastritis characterized by mucosal protrusions with central depressions, typically found in the stomach. This paper discusses the first reported case of VG extending into the duodenum, involving a 68-year-old immunocompromised patient with a complex medical history, including prostate cancer and multiple comorbidities. The diagnosis was complicated by the presence of Helicobacter pylori, which was treated successfully with eradication therapy consisting of amoxicillin and clarithromycin along with omeprazole. Highlighting the potential for VG to affect areas beyond the stomach, this case underscores the importance of considering VG in patients with unexplained hypoalbuminemia and gastrointestinal symptoms.